DOI: http://dx.doi.org/10.18203/issn.2454-5929.ijohns20180708

Evaluation of efficacy of fixed dose combination of montelukast and levocetirizine compared to monotherapy of montelukast and levocetirizine in patients with seasonal allergic rhinitis

Kiran Bylappa, Wilma Delphine Silvia C. R.

Abstract


Background: Allergic rhinitis (AR) is a global health problem. Almost 10%–25% of population worldwide is affected by AR. Seasonal allergic rhinitis (SAR) is caused by an IgE-mediated reaction to seasonal aeroallergens and is fairly easy to identify because of the rapid and reproducible onset and offset of symptoms in association with pollen exposure. SAR can result in hyperresponsiveness to allergens. Treatment of allergic rhinitis is aimed to achieve optimal symptom control and reduce nasal congestion, sneezing and rhinorrhea over the course of the entire day and night.

Methods: Out of total 274 subjects, 92 subjects in the FDC of montelukast 10 mg and levocetrizine 5 mg group, 92 subjects in montelukast 10 mg group and 90 subjects in levocetrizine 5 mg group were enrolled in the study. The total study duration was 16 days. Criteria for evaluation of primary efficacy were mean change in daytime nasal symptoms score from baseline to end of treatment. Mean change in night time symptoms score from baseline to end of treatment. Mean change in daytime eye symptoms score from baseline to end of treatment. Patient's and physician's global evaluation of allergic rhinitis at the end of treatment. Mean change in rhinoconjunctivitis quality-of life score from baseline to end of treatment.  

Results: Primary efficacy endpoint that fixed dose combination (FDC) of montelukast 10 mg and levocetirizine 5 mg was superior to montelukast 10 mg monotherapy or levocetirizine 5mg monotherapy in the treatment of patients with seasonal allergic rhinitis. Other secondary endpoints and global impression results are also supporting the therapeutic benefit of fixed dose combination over monotherapy.

Conclusions: FDC of montelukast 10 mg and levocetirizine 5 mg was superior to montelukast 10 mg monotherapy or levocetirizine 5 mg monotherapy in the treatment of patients with seasonal allergic rhinitis.


Keywords


Seasonal allergic rhinitis, Montelukast, Levocetirizine, Rhinorrhea, Nasal congestion

Full Text:

PDF

References


Wallace DV, Dykewicz MS, Bernstein DI. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2):1-84.

Singh AB, Kumar P. Aeroallergens in clinical practice of allergy in India. An overview. Ann Agric Environ Med. 2003;10(2):131-6.

Singh AB, Shahi S. Aeroallergens in clinical practice of allergy in India- ARIA Asia Pacific Workshop report. Asian Pac J Allergy Immunol. 2008;26(4):245-56.

Kubavat AH, Pawar P, Mittal R. An open label, active controlled, multicentric clinical trial to assess the efficacy and safety of fluticasone furoate nasal spray in adult Indian patients suffering from allergic rhinitis. J Assoc Physicians India. 2011;59:424-8.

Shah A, Pawankar R. Allergic rhinitis and co-morbid asthma: perspective from India -- ARIA Asia- Pacific Workshop report. Asian Pac J Allergy Immunol. 2009;27(1):71-7.

Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Acad allergol Clin Immunol Allergy 2000;55:116-34.

Howarth PH, Salagean M, Dokie D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000;55(64):7-16.

Lagos J.A., Marshall, G.D., Montelukast in the management of allergic rhinitis. Ther Clin Risk Manag. 2007;3:327-32.

Storms W. Allergic rhinitis-induced nasal congestion: its impact on sleep quality. Prim Care Respir J. 2008;17(1):7-18.

Deem K, Ponikau P. Management of Allergic Rhinitis—Implementation of Evidence-based Guidelines. Touch Briefings. 2008.

Mösges R, König V, Köberlein J. The effectiveness of levocetirizine in comparison with loratadine in treatment of allergic rhinitis--a meta-analysis. Allergol Int. 2011;60(4):541-6.

Philip G., Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double blind, Placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020-8.

Knapp H. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990;323:1745-48.

Grossman J, Ratner PH, Nathan R. Pranlukast, an oral leukotriene receptor antagonist, relieves symptoms in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1997;99:443.

Gupta V, Matreja PS. Efficacy of montelukast and levocetirizine as treatment for allergic rhinitis. J Allergy Ther. 2010;1:103.

Adsule SM, Misra D. Long term treatment with montelukast and levocetirizine combination in persistent allergic rhinitis: Review of recent evidence. J Indian Med Assoc. 2010;108:381–2.

Mullol J, Bachert C, Bousquet J. Management of persistent allergic rhinitis: Evidence-based treatment with levocetirizine. Ther Clin Risk Manag. 2005;1:265–71.